Advertisement

Diabetic Eye Disease

  • Daniel S. CasperEmail author
  • Jonathan S. Chang
Chapter

Abstract

In the year 2000, the number of patients in the United States known to have diabetic retinopathy was believed to be about 4 million. Recent National Eye Institute studies estimated that among people older than 40 years of age, there were approximately 8 million known cases in 2010 and project that the number of cases of diabetic retinopathy in the United States will most likely double over the next 40 years, to an estimated 15 million in 2050. In 2007, the estimated number of diabetics in the United States was approximately 24 million (NIDDK), yet the prevalence of undiagnosed diabetes cases was estimated to be close to 6 million people; one can assume that the numbers for undiagnosed diabetic eye disease are similarly underestimated. Diabetic retinopathy is cited as the leading cause of new cases of blindness in persons aged 20–74, and about 12% of new cases of blindness yearly are attributed to diabetes. It is believed that in 60–90% of those cases, visual loss could have been prevented with early detection and management. Despite this, it has been estimated that about one-third of US diabetic patients have never had an eye exam, and only two-thirds of those with high-risk proliferative retinopathy or clinically significant macular edema have had an ophthalmic evaluation within 2 years.

Keywords

Diabetic eye disease Eye disease with diabetes Diabetic retinopathy Vitrectomy surgery Laser photocoagulation for diabetic retinopathy Blindness in diabetic retinopathy 

Suggested Reading

  1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.  https://doi.org/10.1016/S0140-6736(09)62124-3. Epub 2010 Jun 26.CrossRefGoogle Scholar
  2. Chew EY, Klein ML, Murphy RP, Remaley NA, Ferris FL 3rd. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early treatment diabetic retinopathy study report no. 20. Arch Ophthalmol. 1995;113(1):52–5.CrossRefGoogle Scholar
  3. Diabetic retinopathy study. Report number 6. Design, methods, and baseline results. Invest Ophthalmol Vis Sci. 1981;21:147–226.Google Scholar
  4. Early Treatment Diabetic Retinopathy Study R. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103:1796–806.CrossRefGoogle Scholar
  5. Elman MJ, Bressler NM, Haijing Qin MS, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14.CrossRefGoogle Scholar
  6. Frank R. Diabetic retinopathy. NEJM. 2004;350:48–58.CrossRefGoogle Scholar
  7. Moss SE, Klein R, Klein BE. Factors associated with having eye examinations in persons with diabetes. Arch Fam Med. 1995;4:529–34.CrossRefGoogle Scholar
  8. Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Columbia University Irving Medical CenterNew YorkUSA
  2. 2.Department of OphthalmologyEdward S. Harkness Eye InstituteNew YorkUSA
  3. 3.Naomi Berrie Diabetes CenterColumbia University Vagelos College of Physicians and SurgeonsNew YorkUSA
  4. 4.Department of Ophthalmology and Visual SciencesUniversity of Wisconsin School of Medicine and Public HealthMadisonUSA

Personalised recommendations